Onesource Specialty Pharma

Onesource Specialty Pharma Receivables/Revenue

The Receivables to Revenue Ratio of Onesource Specialty Pharma (ONESOURCE.NS) as of Nov 7, 2026 is 29.26 %. In the previous year, Receivables to Revenue Ratio was 32.13 % — a change of -8.93% (lower).

Receivables/Revenue

29.26 %

YoY

-8.93%

Last updated:

Receivables to Revenue Ratio of Onesource Specialty Pharma is 2025 29.26 % . Receivables to Revenue Ratio of Onesource Specialty Pharma was 2024 32.13 % . It decreases by -8.93% lower compared to the previous year.

The Onesource Specialty Pharma Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2023
9.87 INR
Jan 1, 2024
32.13 INR
Jan 1, 2025
29.26 INR
The Onesource Specialty Pharma Receivables/Revenue history
YEARReceivables/RevenueYoY
29.26 %-8.93%
32.13 %+225.46%
9.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Onesource Specialty Pharma Stock analysis

What does Onesource Specialty Pharma do? Onesource Specialty Pharma Ltd operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO) within the Life Sciences Tools & Services industry. Based in Bangalore, Karnataka, the India-based company provides vertically integrated biopharma services, focusing on the development and manufacture of complex biologics, biosimilars, and vaccines. Its core offerings include prefilled syringes with or without safety devices, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. The firm supports the development of complex biologics such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and ribonucleic acid (RNA) products. The company generates revenue by catering to a variety of capsule shapes and sizes through its integrated services. These services encompass formulations ranging from traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and su. By providing comprehensive biologics solutions, the firm serves clients requiring advanced manufacturing capabilities for diverse pharmaceutical delivery systems and therapeutic modalities. Onesource Specialty Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onesource Specialty Pharma stock

Receivables to Revenue Ratio of Onesource Specialty Pharma is 29.26 % in 2025.

Receivables to Revenue Ratio of Onesource Specialty Pharma changed from 32.13 % to 29.26 %, representing a -8.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Onesource Specialty Pharma since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Onesource Specialty Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Onesource Specialty Pharma

All Key Metrics — Onesource Specialty Pharma